Drug Profile


Alternative Names: Apatinib mesylate; YN-968-D1

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Advenchen Laboratories LLC
  • Developer Bukwang Pharmaceutical; Fudan University Shanghai Cancer Center; Jiangsu Hengrui Medicine Co.; LSK Biopharma
  • Class Amides; Antineoplastics; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • Phase III Hepatocellular carcinoma; Non-small cell lung cancer
  • Phase II Breast cancer; Colorectal cancer; Solid tumours

Most Recent Events

  • 14 Mar 2017 Jiangsu HengRui Medicine and Beijing Cancer Hospital plan a phase I trial for Ovarian cancer and Breast cancer (Combination therapy) in China (NCT03075462)
  • 02 Mar 2017 LSK Biopharma plans a phase II trial for Colorectal cancer in the EU and South Korea
  • 02 Mar 2017 LSK Biopharma plans a phase II trial for Hepato-cellular carcinoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top